News Breaks |
|
|
| February 1, 2013 |
| 07:55 EDT |  | STJ, STJ, STJ | St. Jude Medical to host investor meeting with a conference call hookup
Investor meeting to be held in New York on February 1 at 8 am. Webcast Link |
|
|
News For STJ From The Last 14 Days Check below for free stories on STJ the last two weeks. |
|
|
| May 23, 2013 |
| 05:44 EDT |  | STJ | St. Jude Medical study of EnligHTN shows sustained blood pressure reduction
St. Jude Medical announced that the company's EnligHTN Multi-Electrode Renal Denervation System provides a safe, rapid and sustained reduction in blood pressure measurements after one year. Patients enrolled in the EnligHTN I trial had an average blood pressure of 176 / 96 mmHg and patients were drug-resistant, meaning their blood pressure could not be controlled through medication. At one year, patients treated with the EnligHTN Renal Denervation System experienced an average systolic blood pressure reduction of 27 mmHg points when measured in an office setting. |
|
| May 20, 2013 |
| 11:12 EDT | | STJ | St. Jude Medical to evaluate defibrilator lead related to reported death
 Subscribe for More Information |
|
| May 16, 2013 |
| 08:05 EDT | | STJ | St. Jude Medical's 3-D vessel reconstruction system approved in Europe
St. Jude Medical announced CE Mark approval of its Ilumien Optis PCI Optimization System, a new technology designed to provide physicians with a comprehensive disease assessment tool for treating patients with coronary artery disease. St. Jude Medical is the only company to provide these tools together in an integrated platform. |
|
| May 14, 2013 |
| 08:09 EDT | | STJ | St. Jude Medical announces first patient enrolled in EnligHTN III study
Subscribe for More Information |
|
| May 9, 2013 |
| 14:01 EDT | | STJ | St. Jude says analysis demonstrates safety, reliability of Optim-insulated leads
Subscribe for More Information |
|
| 09:27 EDT | | STJ | Leerink's medical devices analyst holds a conference call
Subscribe for More Information |
|
|
|
|
|
